Countless lawsuits have been filed against makers of Testosterone Replacement Therapy (TRT). Secondary exposure to TRTs like AndroGel may lead to serious adverse effects like abnormal pubic hair growth and sexual organ enlargement in children.
AndroGel 1% and AndroGel 1.62% are both prescription drugs manufactured by Abbot Laboratories use as daily testosterone replacement therapy. Generally, AndroGel 1.62 % is applied to the skin on upper arms and on shoulders while AndroGel 1 % can be used for the abdomen, uppers arms and shoulders.
Secondary exposure to testosterone, more specifically to children, has serious adverse effects including unexpected sexual organ enlargement. Other side effects noted are acne breakout in women and premature development of pubic hair in children.
Commonly, children ranging from ages of nine months to seven years old are mostly the ones being hit by the adverse effects of secondary TRT exposures but in early 2014, five men filed lawsuits against Abbot Laboratories when they allegedly suffered from mini stroke after using AndroGel.
AndroGel 1% was approved by the Food and Drug Administration in 2000, and the 1.62% version of the drug came in the market during the second quarter of 2011. More than one million prescriptions of AndroGel 1% were dispensed in the U.S market as of 2007 and approximately about thirty thousand of those were for off-label use in women.
It was in May 2009 when the FDA announced that AndroGel must carry a boxed warning which states the possible side effects of this drug to children and women who were inadvertently exposed or being contact with the person using the product. When Androgen 1.62% was released in the market, it already carried a black-box warning.
Those who experienced the serious adverse effects of AndroGel may be eligible for compensation if they file a lawsuit. A Plaintiff’s compensation will depend on the validity and strength of their case.